Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
NCT06911424
Recruiting
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
Gender:
ALL
Ages:
All
Trial Updated:
08/18/2025
Locations: Baxis Site 09, Pittsburgh, Pennsylvania
Conditions: Bacterial Conjunctivitis
Register for Updates
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621
Recruiting
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
08/18/2025
Locations: VYGR Site 840011, Plymouth Meeting, Pennsylvania
Conditions: Alzheimer's Disease (AD)
Register for Updates
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812
Recruiting
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Jefferson University Hospitals, Philadelphia, Pennsylvania
Conditions: Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Register for Updates
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990
Recruiting
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Site #0103, Pittsburgh, Pennsylvania
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Register for Updates
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126
Recruiting
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Melanoma, Cutaneous Malignant
Register for Updates
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301
Recruiting
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Advanced Melanoma
Register for Updates
Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
NCT06693011
Recruiting
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms. Participants will: Undergo treatment with the Contour Neurovascular System Complete follow-up visits at 1month, 12months, and 24 months, following their procedure Report any adverse events to their study team
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/18/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cerebral Aneurysms
Register for Updates
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/18/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Register for Updates
FORWARD CAD IDE Study
NCT06662500
Recruiting
The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithotripsy (IVL) System with the Javelin Coronary IVL Catheter for the treatment of calcified, stenotic de novo coronary artery lesions prior to stenting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Wellspan York Hospital, York, Pennsylvania
Conditions: Coronary Arterial Disease (CAD)
Register for Updates
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
NCT06636383
Recruiting
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/18/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Glycogen Storage Disease Type Ia
Register for Updates
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432
Recruiting
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Alliance Cancer Specialists, PC, Wynnewood, Wynnewood, Pennsylvania
Conditions: Solid Tumours
Register for Updates